Equities research analysts expect Phibro Animal Health (NASDAQ:PAHC) to announce earnings per share of $0.45 for the current quarter, Zacks reports. Zero analysts have made estimates for Phibro Animal Health’s earnings, with the highest EPS estimate coming in at $0.45 and the lowest estimate coming in at $0.44. Phibro Animal Health reported earnings per share of $0.39 in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.4%. The business is expected to announce its next earnings results on Wednesday, August 29th.
On average, analysts expect that Phibro Animal Health will report full year earnings of $1.71 per share for the current fiscal year, with EPS estimates ranging from $1.70 to $1.73. For the next financial year, analysts forecast that the business will report earnings of $1.88 per share, with EPS estimates ranging from $1.86 to $1.90. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Phibro Animal Health.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Monday, May 7th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. Phibro Animal Health had a net margin of 7.24% and a return on equity of 39.91%. The company had revenue of $209.00 million during the quarter, compared to the consensus estimate of $203.03 million. During the same quarter in the prior year, the firm posted $0.37 earnings per share. Phibro Animal Health’s revenue for the quarter was up 10.0% on a year-over-year basis.
PAHC has been the subject of several recent research reports. Credit Suisse Group increased their target price on shares of Phibro Animal Health from $39.00 to $42.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 9th. Zacks Investment Research downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 10th. Morgan Stanley increased their target price on shares of Phibro Animal Health from $30.00 to $36.00 and gave the stock an “underweight” rating in a research note on Wednesday, February 7th. BidaskClub downgraded shares of Phibro Animal Health from a “sell” rating to a “strong sell” rating in a research note on Friday, January 26th. Finally, ValuEngine upgraded shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $38.80.
NASDAQ PAHC opened at $44.80 on Tuesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 3.17 and a quick ratio of 1.73. Phibro Animal Health has a 1 year low of $32.05 and a 1 year high of $46.00. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 29.67, a P/E/G ratio of 2.67 and a beta of 0.92.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 27th. Investors of record on Wednesday, June 6th will be given a $0.10 dividend. The ex-dividend date is Tuesday, June 5th. This represents a $0.40 dividend on an annualized basis and a yield of 0.89%. Phibro Animal Health’s payout ratio is currently 26.49%.
In related news, VP Daniel M. Bendheim sold 3,960 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $40.06, for a total value of $158,637.60. Following the completion of the sale, the vice president now owns 3,860 shares in the company, valued at $154,631.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Bfi Co., Llc sold 9,930 shares of the firm’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $45.05, for a total transaction of $447,346.50. Following the completion of the sale, the insider now owns 2,070 shares of the company’s stock, valued at approximately $93,253.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,628 shares of company stock valued at $7,482,221. 51.88% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in PAHC. First Manhattan Co. acquired a new stake in Phibro Animal Health in the fourth quarter valued at about $100,000. Royal Bank of Canada lifted its position in Phibro Animal Health by 2,104.6% in the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after purchasing an additional 3,641 shares during the period. Dean Capital Investments Management LLC acquired a new stake in Phibro Animal Health in the fourth quarter valued at about $200,000. Highbridge Capital Management LLC acquired a new stake in Phibro Animal Health in the first quarter valued at about $214,000. Finally, Piermont Capital Management Inc. acquired a new stake in Phibro Animal Health in the first quarter valued at about $223,000. Hedge funds and other institutional investors own 48.83% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.